Table 5

Cox proportional hazards model for TLR at 12 months

UnivariateMultivariate model 1Multivariate model 2
HR95% CIP valueHR95% CIP valueHR95% CIP value
DAPT at discharge0.46(0.21 to 1.00)0.050.43(0.17 to 1.08)0.0740.24(0.02 to 3.52)0.297
Cilostazol at discharge1.06(0.46 to 2.46)0.8920.93(0.35 to 2.46)0.8890.29(0.02 to 3.62)0.335
Warfarin at discharge2.87(1.20 to 6.86)0.0182.28(0.90 to 5.79)0.08231.70(1.46 to 685.89)0.028
Male0.85(0.35 to 2.02)0.7060.93(0.38 to 2.24)0.8690.88(0.12 to 6.60)0.898
Prior lower limb revascularisation1.2(0.54 to 2.67)0.6541.24(0.55 to 2.80)0.6022.44(0.31 to 19.50)0.399
Prior coronary revascularisation1.14(0.52 to 2.50)0.7451.44(0.61 to 3.38)0.4071.64(0.23 to 11.85)0.622
Severe calcified lesion0.69(0.45 to 1.07)0.0950.68(0.44 to 1.05)0.0840.44(0.16 to 1.23)0.118
  • Model 1: adjusted for DAPT at discharge, cilostazol at discharge, warfarin at discharge, male, prior lower limb revascularisation, prior coronary revascularisation and severe calcified lesion.

  • Model 2: shared-frailty model with each institution and ID as a random intercept, adjusted for variable in model 1.

  • DAPT, dual antiplatelet therapy; TLR, target lesion revascularisation.